We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117.
- Authors
Bradley, Jeffrey D; Bae, Kyounghwa; Graham, Mary V; Byhardt, Roger; Govindan, Ramaswamy; Fowler, Jack; Purdy, James A; Michalski, Jeff M; Gore, Elizabeth; Choy, Hak
- Abstract
Phase I of Radiation Therapy Oncology Group (RTOG) 0117 determined that 74 Gy was the maximum-tolerated dose with concurrent weekly carboplatin/paclitaxel chemotherapy for inoperable non-small-cell lung cancer (NSCLC). Phase II results are reported here. PATIENTS AND METHODS Patients with unresectable stages I-III NSCLC were eligible. Chemotherapy consisted of weekly paclitaxel at 50 mg/m(2) and carboplatin at area under the curve 2 mg/m(2). The radiation dose was 74 Gy given in 37 fractions. Radiation therapy volumes included those of the gross tumor and involved nodes. The volume of lung at or exceeding 20 Gy (V20) was mandated to be <or= 30%.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Vol 28, Issue 14, p2475
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2009.27.1205